Femtech Market Analysis

Femtech Market Analysis

Femtech market share from the services type segment will register 15% CAGR through 2023-2032. To optimize fertility treatment and postnatal care, health facilities have been leveraging virtual platforms. These trends are attributed to the general rise in the fertility rate. Based on data from the CDC, in 2021, the U.S. witnessed a 1% increase in the birth rate from 2020, with nearly 3.6 million births recorded. Furthermore, the mounting use of digital platforms and advanced products to improve health service delivery and patient outcomes will drive femtech service demand.

Femtech market from pelvic & uterine healthcare applications are expected to account for over 18% business share by 2032. The growing awareness of the impact of pelvic inflammatory diseases on fertility and reproductive health is a major factor driving the usage of femtech products. As per a CDC report, 1 in 8 women with PIDs has trouble conceiving. Uterine cancer has also become a common gynecologic cancer, with new cases continuing to rise across the U.S. These factors will thus promote the use of femtech solutions for pelvic and uterine healthcare.
 

Based on end-use, the diagnostic centers segment is projected to hold over 8% share of the femtech market by 2032. This is on account of the advent of telehealth tools and other digital health technologies to enhance care and reduce patient visits. The prevalence of chronic diseases has also surged over the years. According to WHO estimates, by 2025, nearly 167 million people will become overweight or obese. Since obesity is associated with a range of female reproductive disorders, the high burden of this condition is likely to fuel demand for femtech products in diagnostic centers.
 

Europe femtech market is anticipated to cross USD 35 billion by 2032, due to the strong presence of femtech product developers in the region. Government healthcare spending has also accelerated over recent years. Based on statistics from Eurostat, in 2020, general government expenditure on health amounted to over USD 1,133 billion, or 8% of the GDP, in the EU. These factors, along with the expansion of medical manufacturing, will create lucrative prospects for femtech device manufacturers across the region.